“…As systemic inflammation causes an increase in the levels of various proinflammatory cytokines, which subsequently promote tumor progression because of changes in the cancer microenvironment [19,20], a decreased AGR is thought to correlate with tumor progression. Recently, the AGR was reported to be a prognostic marker in patients with colorectal cancer, lung cancer, breast cancer, and nasopharyngeal carcinoma [16,[21][22][23]. However, there are no reports on the effect of the AGR on mortality in BUC.…”